<p>Verona Pharma plc（纳斯达克代码：VRNA - 获取免费报告）在周二的午盘交易中股价上涨了 3.4%。该公司的股价最高达到 36.14 美元，最后交易价格为 36.14 美元。在午盘交易中，共成交了 52,822 股，较平均交易量 926,335 股下降了 94%。该股票之前的收盘价为 34.94 美元。</p>
<p>获取 <strong>Verona Pharma</strong> 的提醒：</p>
<h2>分析师评级变动</h2>
<p>几位股票分析师对 VRNA 股票发表了看法。HC Wainwright 在 11 月 5 日的报告中将 Verona Pharma 的目标价从 36.00 美元上调至 42.00 美元，并给予该公司 “买入” 评级。Canaccord Genuity Group 在 11 月 5 日的研究报告中将 Verona Pharma 的目标价从 37.00 美元上调至 44.00 美元，并给予该公司 “买入” 评级。Truist Financial 在 10 月 9 日的研究报告中将 Verona Pharma 的目标价从 38.00 美元上调至 44.00 美元，并给予该股票 “买入” 评级。最后，Wells Fargo &amp; Company 在 11 月 5 日的研究报告中将 Verona Pharma 的目标价从 50.00 美元上调至 64.00 美元，并给予该公司 “增持” 评级。根据 MarketBeat 的数据，六位研究分析师对该股票给予了 “买入” 评级，该公司的平均评级为 “买入”，共识目标价为 43.83 美元。</p>
<p><strong>查看我们关于 Verona Pharma 的最新报告</strong></p>
<h2>Verona Pharma 股票表现</h2>
<p>该股票的 50 日移动平均线为 32.92 美元，200 日移动平均线为 23.87 美元。该公司的市值为 30.4 亿美元，市盈率为-19.46，贝塔值为 0.42。该公司的流动比率为 13.03，速动比率为 12.88，债务股本比率为 0.93。</p>
<p>Verona Pharma（纳斯达克代码：VRNA - 获取免费报告）最近于 11 月 4 日发布了其财报。该公司报告的每股收益（EPS）为-0.56 美元，低于分析师的共识预期-0.44 美元，差距为-0.12 美元。该公司在该季度的收入为 562 万美元，而分析师预期为 231 万美元。在去年同期，该公司每股收益为-0.18 美元。分析师预计 Verona Pharma plc 在当前财政年度的每股收益将为-2.11 美元。</p>
<h2>内部交易活动</h2>
<p>在其他消息中，首席财务官 Mark W. Hahn 在 10 月 21 日的交易中出售了 116,696 股 Verona Pharma 股票。该股票以平均价格 4.38 美元出售，总交易额为 511,128.48 美元。交易后，首席财务官现在持有公司 13,973,264 股，价值约为 61,202,896.32 美元。此次交易使其持股比例减少了 0.83%。该出售在向证券交易委员会提交的文件中披露，该文件可通过 SEC 网站访问。此外，首席执行官 David Zaccardelli 在 10 月 18 日的交易中出售了 245,784 股公司的股票。该股票以平均价格 4.38 美元出售，总价值为 1,076,533.92 美元。交易完成后，首席执行官现在持有公司 15,004,920 股，价值为 65,721,549.60 美元。此次交易使其持股比例减少了 1.61%。该出售的披露信息可以在这里找到。在过去 90 天内，内部人士出售了价值 5,004,952 美元的 1,141,944 股公司股票。公司内部人士持有 4.80% 的股票。</p>
<h2>机构资金流入和流出</h2>
<p>对冲基金和其他机构投资者最近对该公司的持仓进行了调整。CWM LLC 在第二季度购买了 Verona Pharma 的新股份，价值约 29,000 美元。EMC Capital Management 在第二季度购买了 Verona Pharma 的新股份，价值约 38,000 美元。GAMMA Investing LLC 在第三季度将其在 Verona Pharma 的持仓增加了 70.6%。GAMMA Investing LLC 现在持有该公司 1,336 股股票，价值 38,000 美元，此前在上个季度又购买了 553 股。Mirae Asset Global Investments Co. Ltd.在第三季度将其在 Verona Pharma 的持仓增加了 25.4%。Mirae Asset Global Investments Co. Ltd.现在持有该公司 2,610 股股票，价值 75,000 美元，此前在上个季度又购买了 529 股。最后，Legato Capital Management LLC 在第二季度购买了 Verona Pharma 的新股份，价值约 154,000 美元。85.88% 的股票由机构投资者和对冲基金持有。</p>
<h2>Verona Pharma 公司简介</h2>
<p>（获取免费报告）</p>
<p>Verona Pharma plc 是一家临床阶段的生物制药公司，专注于开发和商业化治疗呼吸系统疾病的疗法，以满足未满足的医疗需求。该公司的产品候选药物是 ensifentrine，一种吸入式双重抑制剂，针对磷酸二酯酶（PDE）3 和 PDE4 酶，既作为支气管扩张剂又作为抗炎剂，正在进行慢性阻塞性肺病、哮喘和囊性纤维化的三期临床试验。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 Verona Pharma 更好</li>
<li>低市盈率增长股票：解锁投资机会</li>
<li>超级微型计算机飙升 28%：它真的走出困境了吗？</li>
<li>道琼斯工业平均指数（DJIA）是什么？</li>
<li>交易者纷纷回归石油：是什么推动了乐观情绪</li>
<li>医疗保健股票解析：为什么你可能想要投资</li>
<li>3 个热门股票趋势，助力 2025 年</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<p>→ 特朗普赢了。现在购买这枚硬币。（来自 Weiss Ratings）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDQ1OA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDQ1OA"/></p>
<h2>你现在应该投资 1000 美元在 Verona Pharma 吗？</h2>
<p>在你考虑 Verona Pharma 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Verona Pharma 并不在名单上。</p>
<p>虽然 Verona Pharma 目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Verona制药

<p>Verona Pharma 的股票（NASDAQ:VRNA）上涨了 3.4%，至 0.14 美元，交易量显著低于平均水平。分析师对该股票给予了 “买入” 评级，HC Wainwright、Canaccord Genuity、Truist Financial 和 Wells Fargo 均上调了目标价格。公司报告每股亏损 0.56 美元，未能达到预期，但收入为 162 万美元。公司内部人士进行了减持，首席财务官和首席执行官均降低了持股比例。机构持股比例高达 85.88%。Verona Pharma 专注于呼吸系统疾病的治疗，其主要产品候选药物为 ensifentrine</p>

<p>Verona Pharma plc (NASDAQ:VRNA - Get Free Report)'s stock price traded up 3.4% during mid-day trading on Tuesday . The company traded as high as $36.14 and last traded at $36.14. 52,822 shares changed hands during mid-day trading, a decline of 94% from the average session volume of 926,335 shares. The stock had previously closed at $34.94.</p>
<div class="lb-trans"><p>Verona Pharma plc（纳斯达克代码：VRNA - 获取免费报告）在周二的午盘交易中股价上涨了 3.4%。该公司的股价最高达到 36.14 美元，最后交易价格为 36.14 美元。在午盘交易中，共成交了 52,822 股，较平均交易量 926,335 股下降了 94%。该股票之前的收盘价为 34.94 美元。</p>
</div><p>Get <strong>Verona Pharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Verona Pharma</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several equities analysts have weighed in on VRNA shares. HC Wainwright raised their target price on Verona Pharma from $36.00 to $42.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday, November 5th. Canaccord Genuity Group raised their price objective on Verona Pharma from $37.00 to $44.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, November 5th. Truist Financial upped their target price on Verona Pharma from $38.00 to $44.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, October 9th. Finally, Wells Fargo &amp; Company lifted their price target on shares of Verona Pharma from $50.00 to $64.00 and gave the company an &#34;overweight&#34; rating in a research report on Tuesday, November 5th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of &#34;Buy&#34; and a consensus price target of $43.83.</p>
<div class="lb-trans"><p>几位股票分析师对 VRNA 股票发表了看法。HC Wainwright 在 11 月 5 日的报告中将 Verona Pharma 的目标价从 36.00 美元上调至 42.00 美元，并给予该公司 “买入” 评级。Canaccord Genuity Group 在 11 月 5 日的研究报告中将 Verona Pharma 的目标价从 37.00 美元上调至 44.00 美元，并给予该公司 “买入” 评级。Truist Financial 在 10 月 9 日的研究报告中将 Verona Pharma 的目标价从 38.00 美元上调至 44.00 美元，并给予该股票 “买入” 评级。最后，Wells Fargo &amp; Company 在 11 月 5 日的研究报告中将 Verona Pharma 的目标价从 50.00 美元上调至 64.00 美元，并给予该公司 “增持” 评级。根据 MarketBeat 的数据，六位研究分析师对该股票给予了 “买入” 评级，该公司的平均评级为 “买入”，共识目标价为 43.83 美元。</p>
</div><p><strong>Check Out Our Latest Report on Verona Pharma</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Verona Pharma 的最新报告</strong></p>
</div><h2>Verona Pharma Stock Performance</h2>
<div class="lb-trans"><h2>Verona Pharma 股票表现</h2>
</div><p>The stock's 50 day moving average is $32.92 and its two-hundred day moving average is $23.87. The stock has a market capitalization of $3.04 billion, a price-to-earnings ratio of -19.46 and a beta of 0.42. The company has a current ratio of 13.03, a quick ratio of 12.88 and a debt-to-equity ratio of 0.93.</p>
<div class="lb-trans"><p>该股票的 50 日移动平均线为 32.92 美元，200 日移动平均线为 23.87 美元。该公司的市值为 30.4 亿美元，市盈率为-19.46，贝塔值为 0.42。该公司的流动比率为 13.03，速动比率为 12.88，债务股本比率为 0.93。</p>
</div><p>Verona Pharma (NASDAQ:VRNA - Get Free Report) last released its earnings results on Monday, November 4th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.12). The company had revenue of $5.62 million during the quarter, compared to analyst estimates of $2.31 million. During the same quarter in the prior year, the company posted ($0.18) earnings per share. Analysts expect that Verona Pharma plc will post -2.11 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Verona Pharma（纳斯达克代码：VRNA - 获取免费报告）最近于 11 月 4 日发布了其财报。该公司报告的每股收益（EPS）为-0.56 美元，低于分析师的共识预期-0.44 美元，差距为-0.12 美元。该公司在该季度的收入为 562 万美元，而分析师预期为 231 万美元。在去年同期，该公司每股收益为-0.18 美元。分析师预计 Verona Pharma plc 在当前财政年度的每股收益将为-2.11 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><p>In other news, CFO Mark W. Hahn sold 116,696 shares of Verona Pharma stock in a transaction on Monday, October 21st. The shares were sold at an average price of $4.38, for a total transaction of $511,128.48. Following the transaction, the chief financial officer now owns 13,973,264 shares in the company, valued at approximately $61,202,896.32. The trade was a 0.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, CEO David Zaccardelli sold 245,784 shares of the company's stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $4.38, for a total value of $1,076,533.92. Following the completion of the sale, the chief executive officer now owns 15,004,920 shares in the company, valued at $65,721,549.60. This trade represents a 1.61 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,141,944 shares of company stock valued at $5,004,952. 4.80% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他消息中，首席财务官 Mark W. Hahn 在 10 月 21 日的交易中出售了 116,696 股 Verona Pharma 股票。该股票以平均价格 4.38 美元出售，总交易额为 511,128.48 美元。交易后，首席财务官现在持有公司 13,973,264 股，价值约为 61,202,896.32 美元。此次交易使其持股比例减少了 0.83%。该出售在向证券交易委员会提交的文件中披露，该文件可通过 SEC 网站访问。此外，首席执行官 David Zaccardelli 在 10 月 18 日的交易中出售了 245,784 股公司的股票。该股票以平均价格 4.38 美元出售，总价值为 1,076,533.92 美元。交易完成后，首席执行官现在持有公司 15,004,920 股，价值为 65,721,549.60 美元。此次交易使其持股比例减少了 1.61%。该出售的披露信息可以在这里找到。在过去 90 天内，内部人士出售了价值 5,004,952 美元的 1,141,944 股公司股票。公司内部人士持有 4.80% 的股票。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Hedge funds and other institutional investors have recently made changes to their positions in the business. CWM LLC bought a new stake in shares of Verona Pharma during the second quarter valued at approximately $29,000. EMC Capital Management bought a new stake in shares of Verona Pharma during the second quarter worth about $38,000. GAMMA Investing LLC increased its position in shares of Verona Pharma by 70.6% during the third quarter. GAMMA Investing LLC now owns 1,336 shares of the company's stock worth $38,000 after acquiring an additional 553 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Verona Pharma by 25.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,610 shares of the company's stock worth $75,000 after acquiring an additional 529 shares during the last quarter. Finally, Legato Capital Management LLC bought a new position in Verona Pharma in the 2nd quarter valued at about $154,000. 85.88% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近对该公司的持仓进行了调整。CWM LLC 在第二季度购买了 Verona Pharma 的新股份，价值约 29,000 美元。EMC Capital Management 在第二季度购买了 Verona Pharma 的新股份，价值约 38,000 美元。GAMMA Investing LLC 在第三季度将其在 Verona Pharma 的持仓增加了 70.6%。GAMMA Investing LLC 现在持有该公司 1,336 股股票，价值 38,000 美元，此前在上个季度又购买了 553 股。Mirae Asset Global Investments Co. Ltd.在第三季度将其在 Verona Pharma 的持仓增加了 25.4%。Mirae Asset Global Investments Co. Ltd.现在持有该公司 2,610 股股票，价值 75,000 美元，此前在上个季度又购买了 529 股。最后，Legato Capital Management LLC 在第二季度购买了 Verona Pharma 的新股份，价值约 154,000 美元。85.88% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Verona Pharma Company Profile</h2>
<div class="lb-trans"><h2>Verona Pharma 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.</p>
<div class="lb-trans"><p>Verona Pharma plc 是一家临床阶段的生物制药公司，专注于开发和商业化治疗呼吸系统疾病的疗法，以满足未满足的医疗需求。该公司的产品候选药物是 ensifentrine，一种吸入式双重抑制剂，针对磷酸二酯酶（PDE）3 和 PDE4 酶，既作为支气管扩张剂又作为抗炎剂，正在进行慢性阻塞性肺病、哮喘和囊性纤维化的三期临床试验。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Verona Pharma</li>
<li>Low PE Growth Stocks: Unlocking Investment Opportunities</li>
<li>Super Micro Computer Soars 28%: Is It Really Out of the Woods?</li>
<li>What is the Dow Jones Industrial Average (DJIA)?</li>
<li>Traders Are Flocking Back to Oil: What’s Fueling the Optimism</li>
<li>Health Care Stocks Explained: Why You Might Want to Invest</li>
<li>3 Hot Stock Trends to Ride Into 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Verona Pharma 更好</li>
<li>低市盈率增长股票：解锁投资机会</li>
<li>超级微型计算机飙升 28%：它真的走出困境了吗？</li>
<li>道琼斯工业平均指数（DJIA）是什么？</li>
<li>交易者纷纷回归石油：是什么推动了乐观情绪</li>
<li>医疗保健股票解析：为什么你可能想要投资</li>
<li>3 个热门股票趋势，助力 2025 年</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><p>→ Trump won. Buy this coin now. (From Weiss Ratings)(Ad)</p>
<div class="lb-trans"><p>→ 特朗普赢了。现在购买这枚硬币。（来自 Weiss Ratings）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDQ1OA" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=10458&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Verona Pharma right now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Verona Pharma 吗？</h2>
</div><p>Before you consider Verona Pharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Verona Pharma 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verona Pharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Verona Pharma 并不在名单上。</p>
</div><p>While Verona Pharma currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Verona Pharma 目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Verona 制药（NASDAQ:VRNA）股价上涨 3.4% - 仍然值得买入吗？